Home – Cell Symposia: The cancer immunity cycle
Cell Symposia: Infection Biology in the Age of the Microbiome
Related Articles
The OncoAlert Newsletter is NOW OUT Click to Register
The OncoAlert Newsletter is now out for June 23-29, 2023
Home – Cell Symposia: The cancer immunity cycle
Cell Symposia: Infection Biology in the Age of the Microbiome
Home – Cell Symposia: The cancer immunity cycle
Cell Symposia: Infection Biology in the Age of the Microbiome
Certain Breast Cancer Subtypes May Derive a Greater Benefit With Ribociclib Combo vs Chemo
Patients with luminal B and HER2E breast cancer subtypes may have a greater PFS benefit with ribociclib plus endocrine therapy vs combination chemotherapy.
FDA Grants Fast Track Designation to IMM-1-104 in NRAS+ Advanced Melanoma
The FDA has granted fast track designation to IMM-1-104 for the treatment of advanced melanoma.
FDA Approves Ensartinib for Locally Advanced or Metastatic ALK+ NSCLC
The FDA has approved ensartinib for patients with ALK+ locally advanced or metastatic NSCLC who have not previously received an ALK inhibitor.
FDA Approves Ensartinib for Locally Advanced or Metastatic ALK+ NSCLC
The FDA has approved ensartinib for patients with ALK+ locally advanced or metastatic NSCLC who have not previously received an ALK inhibitor.
Order A Complimentary Moffitt License Plate Today
Your investment in a Moffitt specialty plate helps researchers develop innovative medicines and treatment protocols-each of which transform lives, one patient at a time.
NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations
By combining potent targeting of ALK oncoproteins and resistant mutants with brain penetrance and selectivity for ALK over TRK, the ALK inhibitor NVL-655 addresses key…
